Abstract:Key Points: Plasmapheresis is recommended for treating ANCA-associated vasculitis with severe renal and/or lung involvement.We established the cohort being admitted for ANCA-associated vasculitis with active kidney involvement from the 2016–2020 National Inpatient Sample.We described characteristics, inpatient procedures, lengths of stay, hospital costs, and disposition for patients treated with plasmapheresis. Background: Plasmapheresis is currently recommended when ANCA-associated vasculitis (AAV) presents with severe kidney and/or lung involvement. This cross-sectional study aimed at describing characteristics of hospitalized patients diagnosed with AAV with severe kidney involvement undergoing plasmapheresis in the United States. Methods: We defined the study population as adults hospitalized for active kidney involvement with a new diagnosis of AAV (by subtype or unspecified). We established the cohort from the 2016–2020 National Inpatient Sample by International Classification of Diseases, Tenth Revision, Clinical Modification codes. In this cross-sectional study, we described demographic and clinical characteristics, associated inpatient procedures, lengths of stay, hospital costs, and disposition at discharge comparing patients treated and not treated with plasmapheresis. Results: We identified a total of 975 patients with hospitalized AAV with acute kidney involvement in the United States treated by plasmapheresis over the 5-year period. Demographic characteristics of patients who received plasmapheresis were similar to those in patients who did not (n=5670). There were no regional differences in the proportion of patients who received plasmapheresis; however, plasmapheresis was deployed more frequently among patients admitted to urban teaching hospitals relative to rural and non-teaching hospitals. Patients treated with plasmapheresis were more likely to have had AKI (96% versus 90%, P = 0.0007), AKI requiring dialysis (52% versus 16%, P < 0.001), hypoxia (40% versus 16%, P < 0.0001), and respiratory failure requiring mechanical ventilation (13% versus 3%, P = 0.0003). Conclusions: During 2016–2020, plasmapheresis was deployed in approximately 20% of patients being admitted for AAV and acute kidney involvement in the United States. As standards of care and practice evolve, the role of plasmapheresis in the management of AAV with acute kidney involvement will require further study.

Plasmapheresis and RATG‐induced serum sickness

Methylprednisolone and plasmapheresis are effective for life-threatening diffuse alveolar hemorrhage and gastrointestinal hemorrhage in granulomatosis with polyangiitis: A case report and literature review.

Methylprednisolone and Plasmapheresis Are Effective for Life-Threatening Diffuse Alveolar Hemorrhage and Gastrointestinal Hemorrhage in Granulomatosis with Polyangiitis

[Role of plasmapheresis and immunoadsorption in salvage therapy of rheumatological diseases]

Application of Plasmapheresis in Treating the Antibody-Mediated Acute Rejection after Kidney Transplantation

Plasmapheresis combined with rituximab treatment of a case of thrombotic thrombocytopenic purpura with Sjögren syndrome and renal impairment: A case report

Effect of Plasmapheresis on the Efficacy of Rituximab in Antibody-Mediated Rejection Patients

Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM disease

The Role of Plasmapheresis In Pediatric Antibody- Negative Autoimmune Encephalitis

Plasmapheresis, immunosuppressive therapy and anti-GBM disease prognosis: a cohort study of 107 patients

Rabbit Antithymocyte Globulin As First-Line Therapy for Severe Aplastic Anemia

Management and long-term outcome of recurrent idiopathic FSGS in pediatric kidney transplant recipients

Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome

When you think you should transfuse…don't!

Therapeutic plasmapheresis in idiopathic membranous nephropathy anti-PLA2R-related: A case series

Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection

Apparent hemolysis following intravenous antithymocyte globulin treatment in a patient with marrow failure and a paroxysmal nocturnal hemoglobinuria clone

Plasmapheresis in ANCA-Associated Vasculitis with Active Kidney Involvement in the United States (2016-2020): A Cross-Sectional Study

Therapeutic plasma exchange for the management of a type III hypersensitivity reaction and suspected immune-mediated vasculitis assumed to be caused by human albumin administration in a dog.

Reactions to Rapid Infusion of Stable Plasma Protein Solution during Large Volume Plasma Exchange

A Randomized Trial Comparing Imlifidase to Plasmapheresis in Kidney Transplant Recipients With Antibody‐Mediated Rejection